摘要
目的 研究IL -2治疗与肝细胞癌化疗敏感性的关系。方法 采用S -P免疫组织化学方法对 14例术前有IL -2治疗史、12例术前没有IL -2治疗史的肝细胞癌存档石蜡包埋切片组织中MRP1、IL -2受体α链的表达进行检测。结果 IL -2治疗组中IL -2受体α链表达强度为 :0 3 0 19± 0 0 40 2 3 ,明显高于非治疗 (0 2 63 1± 0 0 2 2 2 4,P <0 0 1) ,IL -2治疗组IL -2治疗有效。IL-2治疗组中MRP1表达的强度为 :0 3 3 64± 0 0 44 67,非治疗组为 :0 3 0 0 8± 0 0 3 764 ,两者的差异有显著性意义 (P <0 0 5 )。结论 用IL -2治疗HCC患者 ,在增加机体抗肿瘤免疫的同时增加了肝癌细胞对化疗药物的耐受性 ,因此 ,在以化疗为主要治疗手段时 ,联合应用IL -2会降低治疗效果。
Objective To investigate the relationship between the interleukin-2 (IL-2) treatment and chemotherapeutic sensitivity in hepatocellular carcinoma (HCC). Methods S-P immunohistochemical staining was adopted to determine the expression of multidrugs resistance-associated protein(MRP1) and IL-2 receptor α chain in paraffin embedded HCC tissues of the patients treated with and without IL-2. Results The expression level of IL-2 receptor α-chain in HCC tissues of the patients treated with and without IL-2 was 0.301 9±0.040 23 and 0.263 1±0.022 24, respectively, which had significant difference between the two kinds of HCC tissues. The expression level of MRP1 in the HCC tissues of the patients treated with IL-2 (0.336 4±0.044 67) was markedly higher than that in HCC tissues of the patients treated without IL-2 (0.300 8±0.037 64,t=2.176,P<0.05). Conclusion The data indicated that IL-2 therapy could decrease the chemotherapeutic sensitivity of HCC.
出处
《中国医师杂志》
CAS
2005年第1期11-13,共3页
Journal of Chinese Physician
基金
湖北省自然科学基金资助项目 (2 0 0 4ABA2 4 6)
关键词
IL-2
治疗
肝癌
化疗敏感性
Hepatocellular carcinoma
Multidrugs resistance-associated protein
Interleukin-2
